BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37446915)

  • 1. Electrochemical Synthesis of New Isoxazoles and Triazoles Tethered with Thiouracil Base as Inhibitors of Histone Deacetylases in Human Breast Cancer Cells.
    Vishwanath D; Xi Z; Ravish A; Mohan A; Basappa S; Krishnamurthy NP; Gaonkar SL; Pandey V; Lobie PE; Basappa B
    Molecules; 2023 Jul; 28(13):. PubMed ID: 37446915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of 1,2-benzisoxazole tethered 1,2,3-triazoles that exhibit anticancer activity in acute myeloid leukemia cell lines by inhibiting histone deacetylases, and inducing p21 and tubulin acetylation.
    Ashwini N; Garg M; Mohan CD; Fuchs JE; Rangappa S; Anusha S; Swaroop TR; Rakesh KS; Kanojia D; Madan V; Bender A; Koeffler HP; Basappa ; Rangappa KS
    Bioorg Med Chem; 2015 Sep; 23(18):6157-65. PubMed ID: 26299825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Hydroxamic Acids Incorporating 1-((1H-1,2,3-Triazol-4-yl)methyl)- 3-substituted-2-oxoindolines: Synthesis, Biological Evaluation and SAR Analysis.
    Dung DTM; Huan NV; Cam DM; Hieu DC; Hai PT; Huong LT; Kim J; Choi JE; Kang JS; Han SB; Nam NH
    Med Chem; 2018; 14(8):831-850. PubMed ID: 29807520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines.
    Sixto-López Y; Gómez-Vidal JA; de Pedro N; Bello M; Rosales-Hernández MC; Correa-Basurto J
    Sci Rep; 2020 Jun; 10(1):10462. PubMed ID: 32591593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel histone deacetylase inhibitors bearing a 4-piperidin-4-yl-triazole scaffold as antitumor agents.
    Wang Y; Su L; Wang Q; Zhang L; Luan Y
    Drug Dev Res; 2020 Feb; 81(1):52-61. PubMed ID: 31580523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of 4-piperidin-4-yl-triazole derivatives as novel histone deacetylase inhibitors.
    Miao H; Gao J; Mou Z; Wang B; Zhang L; Su L; Han Y; Luan Y
    Biosci Trends; 2019 May; 13(2):197-203. PubMed ID: 31019142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation.
    Aboeldahab AMA; Beshr EAM; Shoman ME; Rabea SM; Aly OM
    Eur J Med Chem; 2018 Feb; 146():79-92. PubMed ID: 29396364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural optimization of tetrahydroisoquinoline-hydroxamate hybrids as potent dual ERα degraders and HDAC inhibitors.
    Xiong S; Wang X; Zhu M; Song K; Li Y; Yang J; Liu X; Liu M; Dong H; Chen M; Chen D; Xiang H; Luo G
    Bioorg Chem; 2023 May; 134():106459. PubMed ID: 36924653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
    He R; Chen Y; Chen Y; Ougolkov AV; Zhang JS; Savoy DN; Billadeau DD; Kozikowski AP
    J Med Chem; 2010 Feb; 53(3):1347-56. PubMed ID: 20055418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of novel histone deacetylase 6 inhibitors with benzyl-triazole as the core skeleton.
    Mou Z; Gao J; Miao H; Zhang L; Su L; Wang B; Luan Y
    Biosci Trends; 2019 Jul; 13(3):267-272. PubMed ID: 31155552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of novel isoxazole-based HDAC inhibitors.
    Conti P; Tamborini L; Pinto A; Sola L; Ettari R; Mercurio C; De Micheli C
    Eur J Med Chem; 2010 Sep; 45(9):4331-8. PubMed ID: 20637529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
    Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
    Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and SAR analysis of 5-chloro-4-((substituted phenyl)amino)pyrimidine bearing histone deacetylase inhibitors.
    Zhang L; Chen Y; Li F; Zhang L; Feng J; Zhang L
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1918-1927. PubMed ID: 35833370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity.
    Gaisina IN; Tueckmantel W; Ugolkov A; Shen S; Hoffen J; Dubrovskyi O; Mazar A; Schoon RA; Billadeau D; Kozikowski AP
    ChemMedChem; 2016 Jan; 11(1):81-92. PubMed ID: 26592932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity.
    Tapadar S; He R; Luchini DN; Billadeau DD; Kozikowski AP
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3023-6. PubMed ID: 19419863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer.
    Ren Y; Li S; Zhu R; Wan C; Song D; Zhu J; Cai G; Long S; Kong L; Yu W
    J Med Chem; 2021 Jun; 64(11):7468-7482. PubMed ID: 34043359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
    Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
    Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
    Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
    ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and molecular docking studies of thymol based 1,2,3-triazole hybrids as thymidylate synthase inhibitors and apoptosis inducers against breast cancer cells.
    Alam MM; Malebari AM; Syed N; Neamatallah T; Almalki ASA; Elhenawy AA; Obaid RJ; Alsharif MA
    Bioorg Med Chem; 2021 May; 38():116136. PubMed ID: 33894490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer activity of N-heteroaryl acetic acid salts against breast cancer; in silico and in vitro investigation.
    Zolghadri S; Ghanbariasad A; Fallahian F; Rahban M; Kalavani M; Bahman Jahromi E; Asadzadeh A; Hajiani M
    Mol Biol Rep; 2022 Jan; 49(1):363-372. PubMed ID: 34714485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.